Differential expression of miR200a-3p and miR21 in grade II–III and grade IV gliomas

Berthois, Yolande; Delfino, Christine; Métellus, Philippe; Fina, Frédéric; Nanni-Metellus, Isabelle; Aswy, Hayat Al; Pirisi, Victor; Ouafik, L’Houcine; Boudouresque, Françoise

doi:10.4161/cbt.28920

Cited by 37 publications

(25 citation statements)

References 66 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, overexpression of miR-200a in grade IV glioma cells increased cell sensitivity to temozolomide. In addition, the miR-200a expression level in sensitive glioma cells to temozolomide was significantly higher than that in less sensitive glioma cells to temozolomide ( 15 ).…”

Section: Discussionmentioning

confidence: 91%

“…miR-200a also played a role in inhibiting gastric adenocarcinoma growth by reducing ZEB1 and ZEB2 expression, inactivating the wnt/β-catenin signaling pathway, and attenuating EMT expression ( 14 ). For gliomas, Berthois et al ( 15 ) reported that the miR-200a expression level in grade IV glioma tissue was lower than those in grade II and III gliomas. Su et al ( 16 ) reported that miR-200a was downregulated in glioma tissue, and overexpression of miR-200a in T98G cells reduced glioma cell proliferation, invasion and metastasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of miR-200a and chemotherapeutic treatment efficacy of glioma

et al. 2018

View full text Add to dashboard Cite

The correlation between miR-200a expression and chemotherapeutic treatment efficacy of glioma was investigated. There were 45 patients with glioma in observation group whose cancer tissues, paracancerous tissues and serum samples were harvested. Additionally, there were 23 healthy subjects in the control group whose serum samples were also collected. The expression levels of miR-200a in cancer tissues, paracancerous tissues and serum samples were measured by real-time fluorescence-based quantitative polymerase chain reaction (qRT-PCR). The t-test and one-way ANOVA were used to compare the serum levels of miR-200a in patients with different clinical features involving age, sex, tumor location, pathological grade and tumor size. All patients in the observation group received temozolomide-based chemotherapy. The serum levels of miR-200a before chemotherapy were compared between patients who were responsive to chemotherapy [complete response (CR) and partial response (PR)] and patients who were not responsive to chemotherapy [stable disease (SD) and progressive disease (PD)]. The expression level of miR-200a in cancer tissue was significantly lower than that in paracancerous tissue (P<0.05). The serum level of miR-200a in patients in the observation group was lower than that in healthy subjects in the control group (P<0.05). No correlations were found between miR-200a expression and patient age, sex and tumor location (P>0.05), but miR-200a expression was found to correlate with pathological grade and tumor size (P<0.05). The expression levels of miR-200a in serum and cancer tissue in chemotherapy-non-responsive patients (SD and PD) were lower than those in chemotherapy-responsive patients (CR and PR, P<0.05). The serum levels of miR-200a in chemotherapy-responsive patients were lower than those in healthy subjects in the control group (P<0.05). Downregulation of miR-200a was associated with onset and progression of glioma, and changes of miR-200a expression levels in patients were correlated with chemotherapeutic treatment efficacy.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Expression of miR-200a and chemotherapeutic treatment efficacy of glioma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In their work, Berthois et al noted the inverse correlation between miR200a levels and O6-methylguanine methyltransferase (MGMT) expression. They also showed that over-expression of miR200a causes sensitization of glioblastoma cells to TMZ and that it can serve as a good marker of tumor chemosensitivity [129]. In another work by Kushwah et al, the role of micro RNA in increasing the chemosensitivity of the tumor was also described.…”

Section: Resistance To Treatmentmentioning

confidence: 95%

Micro RNA Molecules as Modulators of Treatment Resistance, Immune Checkpoints Controllers and Sensitive Biomarkers in Glioblastoma Multiforme

Mazurek

Litak

Kamieniak

et al. 2020

IJMS

View full text Add to dashboard Cite

Based on genome sequencing, it is estimated that over 90% of genes stored in human genetic material are transcribed, but only 3% of them contain the information needed for the production of body proteins. This group also includes micro RNAs representing about 1%–3% of the human genome. Recent studies confirmed the hypothesis that targeting molecules called Immune Checkpoint (IC) open new opportunities to take control over glioblastoma multiforme (GBM). Detection of markers that indicate the presence of the cancer occupies a very important place in modern oncology. This function can be performed by both the cancer cells themselves as well as their components and other substances detected in the patients’ bodies. Efforts have been made for many years to find a suitable marker useful in the diagnosis and monitoring of gliomas, including glioblastoma.

show abstract

“…Knockdown of either miR did not lead to cell death, but enhanced sensitivity to TMZ (Ujifuku et al , 2010 ). Other miRs such as miR-21 are differentially upregulated in GBM compared to lower-grade gliomas (Berthois et al , 2014 ). miR-21 is upregulated in response to TMZ and confers a certain degree of resistance to the drug, while the loss of miR-21 in TMZ-resistant cell lines resensitized them to the drug (Wong et al , 2012 ).…”

Section: Gbm Molecular Pathophysiologymentioning

confidence: 99%

Emerging treatment strategies for glioblastoma multiforme

2014

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the deadliest form of brain tumor with a more than 90% 5-year mortality. GBM has a paltry median survival of 12.6 months attributed to the unique treatment limitations such as the high average age of onset, tumor location, and poor current understandings of the tumor pathophysiology. The resection techniques, chemotherapic strategies, and radiation therapy currently used to treat GBM have slowly evolved, but the improvements have not translated to marked increases in patient survival. Here, we will discuss the recent progress in our understanding of GBM pathophysiology, and the diagnostic techniques and treatment options. The discussion will include biomarkers, tumor imaging, novel therapies such as monoclonal antibodies and small-molecule inhibitors, and the heterogeneity resulting from the GBM cancer stem cell population.

show abstract

Differential expression of miR200a-3p and miR21 in grade II–III and grade IV gliomas

Cited by 37 publications

References 66 publications

Expression of miR-200a and chemotherapeutic treatment efficacy of glioma

Expression of miR-200a and chemotherapeutic treatment efficacy of glioma

Micro RNA Molecules as Modulators of Treatment Resistance, Immune Checkpoints Controllers and Sensitive Biomarkers in Glioblastoma Multiforme

Emerging treatment strategies for glioblastoma multiforme

Contact Info

Product

Resources

About